TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00191724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
Study: NCT02086994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: given after the delivery of the anterior shoulder of the baby.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbetocin
Description: given after delivery of anterior shoulder
Study: NCT03758144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 200 MG
Description: patients with type 2 diabetes and gut dysbiosis will be given rifaximin
Study: NCT02405845

Intervention type: RADIATION
Group type: OTHER
Intervention: Computed Tomographic Angiogram
Description: 1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
Study: NCT00814528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA plus Blu-Light
Description: 20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, Imiquimod or treatment with cryotherapy
Description: Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
Study: NCT03958955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study: NCT01453712

Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Control group
Description: Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
Study: NCT03280420

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early catheter removal
Description: Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late catheter removal
Description: Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy.
Study: NCT00390858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
Study: NCT03325361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tube drain insertion
Description: A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
Study: NCT00142584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol (NEB)
Description: Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol (MET)
Description: Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
Study: NCT03664557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ER Reboa TM Catheter
Description: During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
Study: NCT03435744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Description: Simvastatin 20 mg added to TAU for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matched placebo added to TAU for 3 months
Study: NCT04387851

Intervention type: BEHAVIORAL
Intervention: Placebo induction
Description: The placebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce placebo effects on somatosensory sensations.

Intervention type: BEHAVIORAL
Intervention: Control
Description: Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).

Intervention type: BEHAVIORAL
Intervention: Control
Description: Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).

Intervention type: BEHAVIORAL
Intervention: Nocebo
Description: The nocebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce nocebo effects on somatosensory sensations.
Study: NCT02309489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner involvement
Description: Partner is involved in maternity care
Study: NCT01830699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept
Description: 160 mg intra-bursal once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: 2 cc (40 mg/mL) triamcinolone intra-bursal once
Study: NCT01986985

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MRI system
Description: Compared to PET CT
Study: NCT01862198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided biliary drainage with a hybrid metallic stent
Description: EUS-guided biliary drainage with a newly designed hybrid metallic stent
Study: NCT01122706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taiji training
Description: Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
Study: NCT02953054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMTS
Description: DMTS applied before surgery and worn for 72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching patches that have no active drug applied before surgery and worn for 72 hours.
Study: NCT02734238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sesame Oil
Description: 200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone enanthate
Description: 200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
Study: NCT01845350

Intervention type: OTHER
Group type: OTHER
Intervention: M2 macrophage introduction
Description: * Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~* Intrathecal introduction of autologous M2 macrophages
Study: NCT01639651

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior capsule stretching
Description: Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
Study: NCT02821481

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00191724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: 1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous (IV), one infusion, over 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (Activated)
Description: 12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (Activated)
Description: 18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (Activated)
Description: 24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
Study: NCT04378829

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
Description: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
Description: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
Description: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
Study: NCT03232814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based walking
Description: The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
Study: NCT02430948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Color-coded materials
Description: A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Color-coded materials
Description: A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Academic detailing
Description: Educational outreach to address the rationale and data supporting recommendations for and against screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Academic detailing
Description: Educational outreach to address the rationale and data supporting recommendations for and against screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard support
Description: Screening recommendations presented in standard format

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard support
Description: Screening recommendations presented in standard format

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No academic detailing
Description: Physician receives study orientation for not the academic detailing curriculum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No academic detailing
Description: Physician receives study orientation for not the academic detailing curriculum
Study: NCT02637505

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic microfracture (MF)
Description: Arthroscopy With microfracture procedure
Study: NCT02669173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
Study: NCT04359069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urinary catheter removal on postoperative day 1
Description: Urinary catheter will be removed on day 1 (experimental) instead of day 3 (standard of care).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urinary catheter removal on postoperative day 3
Description: Urinary catheter will be removed on day 3 (standard of care)
Study: NCT03065049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Facilitated Counseling
Description: Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit activity tracker
Description: Participants will be given a Fitbit activity tracker to monitor physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit activity tracker
Description: Participants will be given a Fitbit activity tracker to monitor physical activity.
Study: NCT04382313

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: the adequate hydration group guided by Vigileo
Description: If the patient is mechanically ventilated, the following scheme is adopted: if SVV≤10%, then adjust the rehydration speed to 1 ml/kg/h; if 10%\<SVV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if SVV≥15%, then adjust the rehydration speed to 3 ml/kg/h. The hydration lasts 24 hours after operation, and the rehydration speed is changed according to the SVV. If the patient does not use mechanical ventilation, the following scheme is adopted: 250ml normal saline is administered within 10 minutes after direct PCI, and the rehydration volume changes to 125ml in patients with mild-to-moderate congestive heart failure. If the increment of SV≥15%, then adjust the rehydration speed to 3 ml/kg/h; if 10%≤the increment of SV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if the increment of SV\<10%, then adjust the rehydration speed to 1 ml/kg/h. Reassessed every 1 hour until SV is stable，and the hydration also lasts 24 hours after operation.
Study: NCT02325466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: ticagrelor 90 mg
Study: NCT02821481

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscular endurance exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Muscular endurance exercise
Study: NCT01506479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Exercise
Description: Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous Exercise
Description: Endurance exercise at 80-85% HR max, 4x/wk for 6 months.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Intervention
Description: No-exercise control (i.e., usual care);
Study: NCT02651298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Co2-laser
Description: laser treatment
Study: NCT02637505

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arthroscopic debridement (AD)
Description: Arthroscopy With debridement procedure
Study: NCT04544098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Description: The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
Study: NCT03231865

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive measurement of ZincProtoporphyrin IX
Description: Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
Study: NCT00450450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Patients undergo allogeneic BMT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic bone marrow transplantation
Description: Patients undergo allogeneic BMT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study: NCT01148758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5323441
Description: cohorts receiving multiple doses iv
Study: NCT03886376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Massage
Description: The deep massage group received 12 minutes of massage on the legs, arms and the back with three different sliding pressures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Massage
Description: The superficial massage group received 12 minutes of only one sliding pressure performed on the legs, arms and the back.
Study: NCT03386240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)
Description: The intervention consists of using Plus group (Triclosan-coated Sutures)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vicryl, monocryl, PDS (not coated with triclosan)
Description: Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
Study: NCT04075058

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation therapy
Study: NCT01716351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients
Description: A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
Study: NCT02865187

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 600IU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 600IU/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Description: Hormonal contraceptives
Study: NCT01412346

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Effects of a Nordic diet rich in plant-based foods and fish
Description: The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effects of a Nordic diet rich in plant-based foods and fish
Description: The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
Study: NCT02978547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 500Mg Tablet
Description: In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
Study: NCT01495130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Description: Undergo transrectal ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo robotic-assisted laparoscopic prostatectomy
Study: NCT01430156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heme arginate (Normosang)
Description: 3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.